Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Abstract

Nivolumab plus cabozantinib had significant benefits over sunitinib with respect to progression-free survival, overall survival, and likelihood of response in patients with previously untreated advanced renal-cell carcinoma. (Funded by Bristol Myers Squibb and others; CheckMate 9ER ClinicalTrials.gov number, NCT03141177.).

Keywords

CabozantinibSunitinibNivolumabRenal cell carcinomaMedicineOncologyInternal medicineTyrosine-kinase inhibitorUrologyImmunotherapyCancer

MeSH Terms

AdultAgedAged80 and overAnilidesAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsB7-H1 AntigenCarcinomaRenal CellFemaleHumansIntention to Treat AnalysisKidney NeoplasmsMaleMiddle AgedNivolumabProgression-Free SurvivalProportional Hazards ModelsPyridinesQuality of LifeReceptor Protein-Tyrosine KinasesSunitinibSurvival Analysis

Affiliated Institutions

Related Publications

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

Robert J. Motzer , Nizar M. Tannir , Ray McDermott +29 more

Overall survival and objective response rates were significantly higher with nivolumab plus ipilimumab than with sunitinib among intermediate- and poor-risk patients with previo...

2018 New England Journal of Medicine 4403 citations

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

James Larkin , Vanna Chiarion‐Sileni , René González +28 more

BACKGROUND Nivolumab plus ipilimumab or nivolumab alone resulted in longer progression-free and overall survival than ipilimumab alone in a trial involving patients with advance...

2019 New England Journal of Medicine 3500 citations

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

F. Stephen Hodi , Steven O’Day , David F. McDermott +26 more

Ipilimumab, with or without a gp100 peptide vaccine, as compared with gp100 alone, improved overall survival in patients with previously treated metastatic melanoma. Adverse eve...

2010 New England Journal of Medicine 14794 citations

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

Suzanne L. Topalian , F. Stephen Hodi , Julie R. Brahmer +27 more

Anti-PD-1 antibody produced objective responses in approximately one in four to one in five patients with non-small-cell lung cancer, melanoma, or renal-cell cancer; the adverse...

2012 New England Journal of Medicine 12335 citations

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

Masatoshi Kudo , Richard S. Finn , Shukui Qin +19 more

2018 The Lancet 5118 citations

Publication Info

Year: 2021
Type: article
Volume: 384
Issue: 9
Pages: 829-841
Citations: 1584
Access: Closed

External Links

Download PDF (Free) View on DOI.org PubMed Semantic Scholar

Social Impact

Altmetric

Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1584

OpenAlex

Influential

1421

CrossRef

Cite This

APA Style

                            
                                
                                    Toni K. Choueiri, 
                                
                                    Thomas Powles, 
                                
                                    Mauricio Burotto
                                
                                et al.
                            
                            (2021). 
                            Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. 
                            New England Journal of Medicine
                            , 384
                            (9)
                            , 829-841.
                            https://doi.org/10.1056/nejmoa2026982
                        

Identifiers

DOI: 10.1056/nejmoa2026982
PMID: 33657295
PMCID: PMC8436591

Data Quality

Data completeness: 90%